CompletedPhase 4

Combination Treatment of Intravitreal Ranibizumab, Focal/Grid Laser and Panretinal Photocoagulation in Patients With Diabetic Macula Edema

Japan40 participantsStarted 2014-04

Plain-language summary

The purpose of this study is to evaluate the mean gain in best corrected visual acuity and the number of intravitreal ranibizumab (IVR) injections under the combination treatment of IVR, focal/grid laser and panretinal photocoagulation. Our hypothesis is that suitable photocoagulation decreases the number of IVR injections.

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * stable medication for the management of diabetes within 3 months * visual impairment due to focal or diffuse diabetic macula edema * decreased vision due to diabetic macula edema and not other causes Exclusion Criteria: * concomitant conditions in the study eye that could prevent the improvement in VA on the study * active intraocular inflammation or infection in either eye * uncontrolled glaucoma in either eye * treatment with antiangiogenic drugs in the study eye within 3 months * history of stroke and uncontrolled hypertension

What they're measuring

best corrected visual acuity

Timeframe: every month, up to 36 months

Trial details

NCT IDNCT02131350

SponsorShinshu University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-03

View on ClinicalTrials.gov More Diabetic Macula Edema trials